Trials / Completed
CompletedNCT02371707
Bioequivalence Study of Idalopirdine Tablets 60 mg
Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study aims to establish bioequivalence between two tablet formulations of idalopirdine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idalopirdine 60 mg formulation A (test) | Tablet for oral use, single dose |
| DRUG | Idalopirdine 60 mg formulation B (reference) | Tablet for oral use, single dose |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2015-02-26
- Last updated
- 2015-05-07
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02371707. Inclusion in this directory is not an endorsement.